GlassScriptPhysician profile
Michel Matthew Joffe
NPI 1154347102
$10,374.63
in general payments reported to CMS, 2019-2025
36 companies · $246 in 2025
The $246 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,077 · 2020: $854 · 2021: $958 · 2022: $232 · 2023: $3,012 · 2024: $997 · 2025: $246.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,755 · Consulting Fee: $500.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,754.74 |
| Consulting Fee | $500.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,229.50 | 2019-2022 | |
| Kowa Pharmaceuticals America, INC. | $998.32 | 2019-2023 | Livalo, Seglentis |
| Amgen INC. | $831.49 | 2019-2024 | Repatha, Tavneos, Krystexxa |
| Astrazeneca Pharmaceuticals LP | $798.58 | 2019-2024 | Farxiga, Andexxa |
| Gilead Sciences, INC. | $720.72 | 2022-2024 | Epclusa, Veklury, Livdelzi |
| Abbvie INC. | $627.57 | 2021-2023 | |
| Cumberland Pharmaceuticals, INC. | $381.88 | 2019-2023 | Vibativ |
| Allergan, INC. | $373.14 | 2019-2020 | |
| Novo Nordisk INC | $370.28 | 2019 | |
| Vifor Pharma, INC. | $231.88 | 2019-2025 | Veltassa |
| Amarin Pharma, INC. | $230.57 | 2019-2020 | |
| Biogen, INC. | $229.84 | 2019-2020 | |
| Otsuka America Pharmaceutical, INC. | $226.16 | 2019-2023 | Rexulti |
| Viiv Healthcare Company | $223.50 | 2019-2021 | |
| Lilly USA, LLC | $216.34 | 2019 |
Show all 36 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michel Joffe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.